OTCMKTS:ARDMQ

Aradigm Competitors

$0.05
0.00 (0.00 %)
(As of 06/30/2020)
Add
Compare
Today's Range
$0.05
Now: $0.05
$0.05
50-Day Range
$0.05
MA: $0.05
$0.05
52-Week Range
$0.02
Now: $0.05
$0.20
VolumeN/A
Average Volume21,923 shs
Market Capitalization$764,000.00
P/E RatioN/A
Dividend YieldN/A
Beta2.91

Competitors

Aradigm (OTCMKTS:ARDMQ) Vs. NIMU, RSLSD, MAGAA, NXNN, IMRSQ, and ECTE

Should you be buying ARDMQ stock or one of its competitors? Companies in the industry of "electromedical equipment" are considered alternatives and competitors to Aradigm, including Non-Invasive Monitoring Systems (NIMU), ReShape Lifesciences (RSLSD), Magna-Lab (MAGAA), Nexeon MedSystems (NXNN), IMRIS (IMRSQ), and Echo Therapeutics (ECTE).

Non-Invasive Monitoring Systems (OTCMKTS:NIMU) and Aradigm (OTCMKTS:ARDMQ) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their earnings, risk, valuation, profitability, analyst recommendations, institutional ownership and dividends.

Profitability

This table compares Non-Invasive Monitoring Systems and Aradigm's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Non-Invasive Monitoring SystemsN/A-2,509.09%-80.19%
AradigmN/AN/AN/A

Analyst Recommendations

This is a breakdown of current ratings and target prices for Non-Invasive Monitoring Systems and Aradigm, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Non-Invasive Monitoring Systems0000N/A
Aradigm0000N/A

Valuation & Earnings

This table compares Non-Invasive Monitoring Systems and Aradigm's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Non-Invasive Monitoring SystemsN/AN/A$-160,000.00N/AN/A
AradigmN/AN/AN/AN/AN/A

Volatility & Risk

Non-Invasive Monitoring Systems has a beta of 0.23, meaning that its share price is 77% less volatile than the S&P 500. Comparatively, Aradigm has a beta of 2.91, meaning that its share price is 191% more volatile than the S&P 500.

Summary

Aradigm beats Non-Invasive Monitoring Systems on 3 of the 3 factors compared between the two stocks.

ReShape Lifesciences (OTCMKTS:RSLSD) and Aradigm (OTCMKTS:ARDMQ) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their profitability, valuation, risk, dividends, institutional ownership, analyst recommendations and earnings.

Earnings & Valuation

This table compares ReShape Lifesciences and Aradigm's gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
ReShape Lifesciences$610,000.000.00$-81,150,000.00N/AN/A
AradigmN/AN/AN/AN/AN/A

Aradigm has lower revenue, but higher earnings than ReShape Lifesciences.

Profitability

This table compares ReShape Lifesciences and Aradigm's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
ReShape Lifesciences-668.58%-163.22%-52.10%
AradigmN/AN/AN/A

Volatility & Risk

ReShape Lifesciences has a beta of 2.03, meaning that its share price is 103% more volatile than the S&P 500. Comparatively, Aradigm has a beta of 2.91, meaning that its share price is 191% more volatile than the S&P 500.

Analyst Ratings

This is a summary of recent ratings and price targets for ReShape Lifesciences and Aradigm, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
ReShape Lifesciences0000N/A
Aradigm0000N/A

Summary

Aradigm beats ReShape Lifesciences on 4 of the 5 factors compared between the two stocks.

Aradigm (OTCMKTS:ARDMQ) and Magna-Lab (OTCMKTS:MAGAA) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, risk, institutional ownership, valuation, dividends, analyst recommendations and earnings.

Analyst Recommendations

This is a breakdown of recent ratings and recommmendations for Aradigm and Magna-Lab, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Aradigm0000N/A
Magna-Lab0000N/A

Volatility and Risk

Aradigm has a beta of 2.91, meaning that its share price is 191% more volatile than the S&P 500. Comparatively, Magna-Lab has a beta of 5.2, meaning that its share price is 420% more volatile than the S&P 500.

Valuation & Earnings

This table compares Aradigm and Magna-Lab's revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
AradigmN/AN/AN/AN/AN/A
Magna-LabN/AN/A$-130,000.00N/AN/A

Profitability

This table compares Aradigm and Magna-Lab's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
AradigmN/AN/AN/A
Magna-LabN/A-12.32%42,399.99%

Summary

Magna-Lab beats Aradigm on 2 of the 3 factors compared between the two stocks.

Aradigm (OTCMKTS:ARDMQ) and Nexeon MedSystems (OTCMKTS:NXNN) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, valuation, institutional ownership, analyst recommendations, dividends, earnings and profitability.

Valuation and Earnings

This table compares Aradigm and Nexeon MedSystems' revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
AradigmN/AN/AN/AN/AN/A
Nexeon MedSystemsN/AN/AN/AN/AN/A

Profitability

This table compares Aradigm and Nexeon MedSystems' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
AradigmN/AN/AN/A
Nexeon MedSystemsN/AN/AN/A

Analyst Ratings

This is a breakdown of recent ratings for Aradigm and Nexeon MedSystems, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Aradigm0000N/A
Nexeon MedSystems0000N/A

Volatility & Risk

Aradigm has a beta of 2.91, meaning that its stock price is 191% more volatile than the S&P 500. Comparatively, Nexeon MedSystems has a beta of 12.71, meaning that its stock price is 1,171% more volatile than the S&P 500.

Summary

Nexeon MedSystems beats Aradigm on 1 of the 1 factors compared between the two stocks.

IMRIS (OTCMKTS:IMRSQ) and Aradigm (OTCMKTS:ARDMQ) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their risk, institutional ownership, earnings, profitability, dividends, valuation and analyst recommendations.

Analyst Ratings

This is a summary of current recommendations and price targets for IMRIS and Aradigm, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
IMRIS0000N/A
Aradigm0000N/A

Earnings and Valuation

This table compares IMRIS and Aradigm's top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
IMRISN/AN/AN/AN/AN/A
AradigmN/AN/AN/AN/AN/A

Volatility & Risk

IMRIS has a beta of -10.69, meaning that its stock price is 1,169% less volatile than the S&P 500. Comparatively, Aradigm has a beta of 2.91, meaning that its stock price is 191% more volatile than the S&P 500.

Profitability

This table compares IMRIS and Aradigm's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
IMRISN/AN/AN/A
AradigmN/AN/AN/A

Summary

Aradigm beats IMRIS on 1 of the 1 factors compared between the two stocks.

Echo Therapeutics (OTCMKTS:ECTE) and Aradigm (OTCMKTS:ARDMQ) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, profitability, institutional ownership, earnings, dividends, risk and analyst recommendations.

Profitability

This table compares Echo Therapeutics and Aradigm's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Echo TherapeuticsN/AN/AN/A
AradigmN/AN/AN/A

Valuation and Earnings

This table compares Echo Therapeutics and Aradigm's top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Echo TherapeuticsN/AN/AN/AN/AN/A
AradigmN/AN/AN/AN/AN/A

Analyst Recommendations

This is a summary of current ratings and target prices for Echo Therapeutics and Aradigm, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Echo Therapeutics0000N/A
Aradigm0000N/A

Volatility and Risk

Echo Therapeutics has a beta of 7.09, meaning that its stock price is 609% more volatile than the S&P 500. Comparatively, Aradigm has a beta of 2.91, meaning that its stock price is 191% more volatile than the S&P 500.

Summary

Echo Therapeutics beats Aradigm on 1 of the 1 factors compared between the two stocks.


Aradigm Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
NIMU
Non-Invasive Monitoring Systems
0.5$0.03flat$2.49 millionN/A0.00Upcoming Earnings
RSLSD
ReShape Lifesciences
0.4N/AN/A$1.94 million$610,000.000.00High Trading Volume
MAGAA
Magna-Lab
0.7$1.09flat$1.29 millionN/A6.06Gap Down
Nexeon MedSystems logo
NXNN
Nexeon MedSystems
0.7$0.55flat$1.12 millionN/A0.00
IMRIS logo
IMRSQ
IMRIS
0.5$0.01flat$364,000.00N/A0.00Gap Up
Echo Therapeutics logo
ECTE
Echo Therapeutics
0.5$0.03flat$356,000.00N/A0.00
SCIE
SpectraScience
0.5$0.00flat$265,000.00N/A0.00Decrease in Short Interest
News Coverage
ULGX
Urologix
0.6$0.01flat$153,000.00N/A0.00Gap Up
AKSY
Aksys
0.0$0.00flat$0.00N/A0.00
Escalon Medical logo
ESMC
Escalon Medical
0.5$0.30flat$0.00$9.40 million-5.04Increase in Short Interest
Gap Up
HRTT
Heart Tronics
0.0$0.15flat$0.00N/A0.00
IVVI
Ivivi Technologies
0.0$0.00flat$0.00N/A0.00High Trading Volume
NWCI
NewCardio
0.5$0.00flat$0.00N/A0.00
PECN
Photoelectron
0.2$0.03flat$0.00N/A0.00Increase in Short Interest
News Coverage
Trimedyne logo
TMED
Trimedyne
0.4$4.25flat$0.00$5.57 million0.00
XCRP
Xcorporeal
0.0$0.00flat$0.00N/A0.00
This page was last updated on 4/14/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.